mRNA-1010 influenza vaccine clinical trials
Also written mRNA-1010.
Its developmentBy Moderna, step by step12 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses mRNA-1010 influenza vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mRNA-1010 influenza vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2022 (6)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
2019-nCoV Vaccine mRNA-1273 (2) · mRNA-1345 respiratory syncytial virus vaccine (2) · MRNA-1045 (2) · mRNA-1647 cytomegalovirus vaccine (1) · mRNA-1273.214 COVID-19 vaccine (1) · MRNA-1230 (1) · mRNA-1073 COVID-19 and influenza combined vaccine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test mRNA-1010 influenza vaccine.
- Dec 2026A Study of Updated mRNA Seasonal Influenza VaccinesPhase 4 · ModernaTX, Inc.
Studies
Open first, then newest update. How each study uses mRNA-1010 influenza vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- A Study of Updated mRNA Seasonal Influenza VaccinesRecruitingPhase 4ModernaTX, Inc.NCT07884175Written as mRNA-1010
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenRecruitingPhase 1ModernaTX, Inc.NCT07870330Written as mRNA-1010
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeCompletedPhase 3ModernaTX, Inc.NCT06602024Written as mRNA-1010
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1010
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsCompletedPhase 2ModernaTX, Inc.NCT05606965Written as mRNA-1010
- Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedPhase 3ModernaTX, Inc.NCT05827978Written as mRNA-1010
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and OlderCompletedPhase 3ModernaTX, Inc.NCT05566639Written as mRNA-1010
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy AdultsCompletedPhase 2ModernaTX, Inc.NCT05868382Written as mRNA-1010
- A Study of mRNA-1010 Seasonal Influenza Vaccine in AdultsCompletedPhase 3ModernaTX, Inc.NCT05415462Written as mRNA-1010
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years OldCompletedPhase 1ModernaTX, Inc.NCT05585632Written as mRNA-1010
- A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years OldCompletedPhase 1/2ModernaTX, Inc.NCT05375838Written as mRNA-1010
- A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy AdultsCompletedPhase 1/2ModernaTX, Inc.NCT04956575Written as mRNA-1010
As the comparator · 2 — what is tested is compared with mRNA-1010 influenza vaccine
- A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy AdultsCompletedPhase 1/2ModernaTX, Inc.NCT05827068Written as mRNA-1010
- A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy AdultsCompletedPhase 1/2ModernaTX, Inc.NCT05333289Written as mRNA-1010
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting2
- A Study of Updated mRNA Seasonal Influenza VaccinesNov 13, 2026NCT07884175
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenOct 28, 2026NCT07870330
Newly registered1
- A Study of Updated mRNA Seasonal Influenza VaccinesOct 20, 2026NCT07884175
Codes
What other systems call mRNA-1010 influenza vaccine · ClinicalTrials.gg INT001886
- MeSH (NLM) C000722747mRNA-1010 influenza vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722747 | mRNA-1010 influenza vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.